Advanced Solid Tumor, HCC, Lymphoma, NSCLC
Conditions
Brief summary
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.
Interventions
DRUGBPI-371153
Subjects will receive BPI-371153 until disease progression
Sponsors
Betta Pharmaceuticals Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Dose escalation phase: Age ≥18 and ≤65 years, male and female patients; Dose expansion phase: Age ≥18, male and female patients; * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1; * Dose escalation phase: histologically or cytologically confirmed locally advanced or metastatic solid tumor patients (excluding HCC patients) or relapsed/refractory lymphoma, who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists; * Dose expansion phase: histologically or cytologically confirmed locally advanced or relapsed/metastatic Non-Driver Mutation NSCLC, relapsed/refractory lymphoma, HCC with Child-Pugh A or B(≤ 7 points), or other diagnosed solid tumor patients who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists; * Evaluable lesion required for dose escalation phase and at least 1 measurable lesion as per RECIST v1.1( for other diagnosed solid tumos excluding HCC), mRECIST(for HCC) or Lugano 2014(for lymphoma); * Adequate organ function;
Exclusion criteria
* Dose escalation phase: Prior immune checkpoint inhibition with anti-programmed cell death-1 (PD1)/programmed death ligand-1(PD-L1) or programmed death ligand-2(PD-L2) therapy; * Dose expansion phase: Prior immune checkpoint inhibition with anti-programmed cell death-1 (PD1)/programmed death ligand-1(PD-L1) or programmed death ligand-2(PD-L2) therapy within 28 days prior to treatment. Subjects with a history of a Grade 3 or higher immune-related AE from prior immunotherapies; * Prior other specific T cell targeting agents; * Use of systemic or absorbable topical corticosteroids therapy(≥ 10 mg/day prednisone or equivalent) two weeks prior to start of treatment. * Inadequate wash-out of prior therapies described per protocol, which may include anti-tumor therapies, tumor adjuvant drugs, organ or stem cell transplantation, moderate or strong CYP3A inhibitor or inducer, and vaccine; * Patients with major surgery within 4 weeks, severe or unstable systemic disease, unstable/symptomatic CNS metastasis, other malignant tumors, autoimmune disease, ILD, clinical significant cardiac disease, bleeding or embolic disease, active infectious disease, conditions affecting drug swallow and absorption, medical history leading to chronic diarrhea, etc; * Pregnancy or lactation; * Other conditions considered not appropriate to participate in this trial by the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The adverse events (AEs) | Through the Phase I, approximately 24 months | Safety and tolerability will be assessed by monitoring frequency, duration and severity of adverse events (AEs) |
| Determine the recommended Phase II dose (RP2D) | Through the Phase I, approximately 24 months | Number of subjects with dose limiting toxicity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the pharmacokinetics of BPI-371153 | Through the Phase I, approximately 24 months | Based on blood plasma concentration |
| Determination of anti-tumor activity of BPI-371153 | Through the Phase I, approximately 24 months | Efficacy assessments (tumor evaluation) will be performed per RECIST1.1, mRECIST or Lugano 2014 depending on tumor type. |
| To explore the levels of expression of PD-L1 associated with BPI-371153 clinical activity | Through the Phase I, approximately 24 months | Based on the levels of expression of PD-L1 and anti-tumor activity of BPI-371153 |
Countries
China
Contacts
Primary ContactYuankai Shi, Ph.D
Outcome results
None listed